...
首页> 外文期刊>Internal medicine. >Neuroleptic Malignant Syndrome Induced by Combination Therapy with Tetrabenazine and Tiapride in a Japanese Patient with Huntington's Disease at the Terminal Stage of Recurrent Breast Cancer
【24h】

Neuroleptic Malignant Syndrome Induced by Combination Therapy with Tetrabenazine and Tiapride in a Japanese Patient with Huntington's Disease at the Terminal Stage of Recurrent Breast Cancer

机译:通过在经常性乳腺癌的末期患者与亨廷顿疾病的日本患者中与四苯嗪和三丙酮的组合治疗诱导的神经抑制性恶性综合征

获取原文
           

摘要

We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease. The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy. She also had advanced breast cancer when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other neuroleptic drugs, particularly in patients with a worsening general condition.
机译:我们在本文中描述了一个81岁的日本女性,其具有神经抑制的恶性综合征,在与亨廷顿氏病联合治疗(75毫克/天)和四甲嗪(12.5毫克/天)开始后36天发生。患者在施用联合治疗之前单独使用Tiapride或四甲苯嗪治疗,没有任何不利影响。当启动组合治疗时,她还有先进的乳腺癌。据我们所知,由于先前,尚未报道由于具有四甲嗪和三丙酮组合治疗而导致的神经抑制性恶性综合征的发生。四萘嗪应与其他神经糖尿病的组合非常小心地施用,特别是在患有恶化的一般病症的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号